O’Brien is worldwide president of BD Peripheral Intervention, where he “developed an extensive and consistent track record of delivering durable, sustainable growth while creating a winning culture,” Zeus said in a news release.
O’Brien held management positions at Bard from 2001, rising to the position of global marketing VP by the time of the company’s December 2017 acquisition by BD.
He’ll replace Steve Peterson, who joined Zeus as SVP of global sales and marketing in 2017 and was promoted to president in 2018 and CEO in 2020.
Zeus recently closed its sale to private equity firm EQT, which said it hired O’Brien after an extensive search.
“Paddy’s deep domain knowledge and experience make him perfectly suited to lead the company through this next phase of growth,” EQT Private Equity Advisory Team Partner Ethan Waxman said in a news release. “We look forward to partnering with Paddy as we make significant investments in increased capacity, process improvement, and product innovation.”
Zeus Executive Chair John Groetelaars said O’Brien has “has deep insights and a keen understanding of the interventional markets targeted by Zeus’ customers.”
“His extensive experience and proven track record make him the ideal leader to steer Zeus through this exciting chapter of growth and advancement,” he continued.
Since its founding in 1966, Zeus has pioneered the design, development, and extrusion of fluoropolymer tubing for medical devices and select industrial applications. The Orangeburg, South Carolina–based company has eight facilities across the U.S. and one in Letterkenny, Ireland, with roughly 2,400 employees serving more than 300 customers in more than 100 countries. Its customers include leading medical device manufacturers, contract device manufacturing organizations and more.
— Editor-in-Chief Chris Newmarker contributed to this report.
